Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were published today in JAMA Oncology and were first presented at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting...
In recognition of her trailblazing work uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, Ph.D., chair of...
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe...
Patients with early-stage breast cancer who had a pathologic complete response (pCR) to neoadjuvant chemotherapy may be able to skip surgery and receive standard radiation treatment with a low chance of disease recurrence, according to a new study from researchers at The University of Texas MD Anderson Cancer Center.
The Phase II trial results, published today in Lancet Oncology, evaluated the likelihood of breast cancer returning...
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the establishment of its internal advisory...
The University of Texas MD Anderson Cancer Center and World Health Organization (WHO) today announced a formal agreement to establish a new...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center will host its virtual Leading Edge of Cancer Research Symposium from November 17-18, 2022...
Three new cancer research projects have been chosen to receive seed funding as part of the program in Oncological Data and Computational Science...
The University of Texas MD Anderson Cancer Center and ARTIDIS AG today announced a strategic alliance to investigate ARTIDIS technology as...